There's been some interesting research on a compound that appears to be a partner peptide for GLP-1. Oxyntomodulin is released in response to a meal and seems to have a significant effect on glucose levels. Our current PharmD candidate, Farhan Guard, from Lake Erie College of Medicine, found out about this peptide while reviewing some information from the Scientific Sessions. Check out "Oxyntomodulin: Partner to GLP-1?" for more information.

Our Clinical Insights interview with Dr. Steven Edelman, by our publisher, continues this week with more of his thoughts on the use of GLP-1 and our Case Study focuses on choosing the right GLP-1 analog therapy.

Over the past few weeks we have been looking at your responses to questions about GLP-1, including mechanisms, interactions, dosing and effectiveness. In this week's analysis if our Survey Data, we focus on your prescribing habits and who you think the best candidates for GLP-1 therapy are.

Oxyntomodulin is a gut peptide released in response to a meal. It is synthesized within specialized enteroendocrine cells called L cells. Oxyntomodulin is released from the intestinal L cells 5-10 minutes after ingestion of food in amounts proportional to calorie intake and levels peak 30 minutes after meals. Oxyntomodulins are thought to act as circulating satiety signals by their effects on the appetite centers such as the hypothalamus and brainstem....

PART 2: Mark, a 55-year-old white man, was diagnosed with type 2 diabetes 3 years ago. At the time of diagnosis his glycosylated hemoglobin (A1c) level was 7.5%, his body mass index (BMI) was 30 kg/m², and his waist circumference was 45 inches. Initially....

This week, we present the second half of our publisher Steve Freed's interview with Dr. Steven Edelman at the recent ADA Scientific Sessions in San Diego.

Dr. Steven Edelman: I think that probably has more promise....

Over the past few weeks we have been looking at your colleagues' responses to questions about GLP-1, including mechanisms, interactions, dosing and effectiveness. Over the next two weeks we will examine some of your opinions on starting doses and selecting patients....

When making a choice amongst GLP-1 Agonists, the number of injections per day and when peak concentrations are reached are both important in selecting therapy. There was almost unanimous consensus that Exenatide is administered twice daily while Liraglutide is given only one time a day. It was interesting to note that....

This week we examine more of your responses regarding GLP-1 therapy....

This week we have some results from our GLP-1 survey. Thanks to the great number of you who participated. As we put together the original survey our first thoughts were to find out what you wanted to know about GLP-1 analogs and what your impressions of the class of drugs are.